DoD Breast Cancer, Breakthrough Award Level 4 | W81XWH 22 BCRP BTA4

Opportunity Information: Apply for W81XWH 22 BCRP BTA4

The DoD Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 (Funding Opportunity Number W81XWH-22-BCRP-BTA4) is built to fund breast cancer research that is genuinely poised to change the game, not just add another incremental step. The central goal is impact: projects should have clear potential to accelerate progress toward ending breast cancer by enabling a fundamentally better approach than what is already approved or even what is currently in clinical development. Applicants are expected to spell out who the work is meant to help, meaning the proposal should identify the specific breast cancer patient populations or at-risk groups that would ultimately benefit if the research succeeds.

This opportunity is specifically for Funding Level 4, which sits at the most advanced end of the Breakthrough Award structure. The program is organized into four funding levels overall, each tied to a different stage on the path to clinical application, and investigators are expected to pick the level that matches the scientific scope rather than trying to force-fit their project to a preferred budget. Level 4 is reserved for large-scale efforts designed to transform and potentially revolutionize clinical management and/or prevention of breast cancer. A key point that is non-negotiable is that a human clinical trial is required, and the award funds must support that clinical trial. Applications that do not truly match the Level 4 intent will not be recommended for funding even if they would have fit better under Levels 1 through 3 (which are offered under separate announcements).

Because these are large, practice-changing clinical efforts, the sponsor expects substantial readiness and execution capability. Principal Investigators are expected to show they can lead a large-scale project successfully, either through their own track record or through a committed collaborating clinical investigator with the right experience. Where the project depends on infrastructure or materials, the application needs to demonstrate access to essentials such as data, human samples, cohorts, and critical reagents. If the proposed work triggers U.S. Food and Drug Administration involvement, there are explicit readiness expectations at the time of application submission: investigators must show that the clinical reagents (such as therapeutics) are available and meet regulatory compliance requirements, that an appropriate subject population is accessible, that patient recruitment projections are credible and validated, and that an IND (Investigational New Drug) or IDE (Investigational Device Exemption) application has been submitted to the FDA when applicable. In other words, this mechanism is meant for teams that are truly prepared to run a serious clinical trial rather than teams still assembling the basic pieces.

The announcement also highlights an optional Partnering PI approach designed for genuine, balanced co-leadership rather than a token collaboration. Under this structure, two PIs can apply together: an Initiating PI who handles most submission administration and a Partnering PI who shares major intellectual responsibility. The expectation is that both PIs contribute meaningfully to the project narrative and statement of work, bring distinct and necessary expertise, and commit comparable and appropriate effort. Budgets are generally expected to be balanced across the two PIs unless there is a strong justification. The program is clear that the partnership should add real value by combining expertise in a way that is better than two separate efforts, and it discourages arrangements where one PI mainly provides samples, models, or an investigational agent while the other does nearly all the research work. If funded, each PI is typically named on an individual award within their organization, reinforcing the idea that this is true co-leadership.

Beyond leadership, the program expects a robust, well-rounded research team with the right breast cancer-related expertise to execute a demanding clinical trial. A distinctive and required feature is embedded consumer advocate participation: every application must include at least two breast cancer consumer advocates who are integrated into the project throughout planning and implementation. These advocates are not meant to be passive advisors who show up for occasional meetings; they should be actively involved in shaping the research question, refining study design, providing oversight input, supporting recruitment considerations, and contributing to evaluation and other key project activities. They must be individuals diagnosed with breast cancer who are active in advocacy organizations, and their role must be independent of employment relationships, meaning they cannot be employees of any participating organization. The intention is to ensure the trial stays grounded in patient realities and priorities, with advocates providing objective feedback on the project and its potential real-world impact for people living with breast cancer or at risk of developing it.

Administratively, this is a discretionary DoD opportunity managed through the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA). The assistance instruments listed include grants and cooperative agreements, and the CFDA number is 12.420. Eligibility is described as unrestricted (open to any entity type, subject to any additional eligibility clarifications in the full announcement). The posting dates in the source information show a creation date of March 16, 2022, and an original closing date of July 27, 2022, with an expected number of awards listed as 1 and an award ceiling shown as 0 in the provided record (which typically signals that applicants must rely on the program announcement for the actual funding limits and structure rather than treating that field as a practical cap). Overall, the opportunity is targeted at teams ready to run a high-stakes breast cancer clinical trial with strong operational readiness, credible regulatory and recruitment planning, meaningful co-leadership options, and deep patient-advocate integration aimed at producing results with real potential to reshape care or prevention.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer, Breakthrough Award Level 4" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 16, 2022.
• Applicants must submit their applications by Jul 27, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 BCRP BTA4

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: